Forward Pharma A/S reported consolidated earnings results for the second quarter and six months ended of June 30, 2016. For the quarter, the company’s net loss attributable to equity holders of the parent was $15.149 million or $0.32 per basic and diluted share against a net loss of $17.691 million, or $0.38 per basic and diluted share for second quarter of 2015.  On a non-GAAP basis, after removing the effect of non-cash income and expense items, the net loss would have been $12.8 million, or $0.27 per basic share. Operating loss was $16.655 million compared to $13.546 million a year ago. For the six months, the company reported operating loss of $29.295 million compared to $21.935 million a year ago. Net loss for the period attributable to equity holders of the parent was $32 million or $0.68 per basic and diluted share compared to $11.665 million or $0.25 per basic and diluted share a year ago. Net cash flows used in operating activities were $15.772 million compared to $13.184 million a year ago. Purchase of equipment was $29,000 compared to $131,000 a year ago.